Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Vitamin C [EPC]
Astacus Astacus (Noble Crayfish) is a biological substance primarily utilized in non-standardized allergenic extracts for the diagnosis and treatment of crustacean-related hypersensitivity. It is classified under several EPC categories, including Vitamin C and various allergenic extracts.
Name
Astacus Astacus
Raw Name
ASTACUS ASTACUS
Category
Vitamin C [EPC]
Drug Count
6
Variant Count
12
Last Verified
February 17, 2026
About Astacus Astacus
Astacus Astacus (Noble Crayfish) is a biological substance primarily utilized in non-standardized allergenic extracts for the diagnosis and treatment of crustacean-related hypersensitivity. It is classified under several EPC categories, including Vitamin C and various allergenic extracts.
Detailed information about Astacus Astacus
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Astacus Astacus.
Astacus Astacus, commonly known as the Noble Crayfish or European crayfish, is a complex biological entity that serves as a primary source for various pharmacological and diagnostic preparations. Within the modern clinical landscape, Astacus Astacus is most prominently recognized as a Non-Standardized Food Allergenic Extract [EPC] and a Non-Standardized Animal Hair Allergenic Extract [EPC]. However, its classification is remarkably broad, extending into categories such as Vitamin C [EPC], Central Nervous System Stimulant [EPC], and Methylxanthine [EPC]. This multifaceted classification reflects the diverse biochemical constituents found within the crayfish matrix, including essential vitamins, bioactive amines, and potent allergenic proteins.
As a therapeutic and diagnostic agent, Astacus Astacus belongs to a class of drugs called Allergenic Extracts. These substances are used by allergists and immunologists to diagnose Type I hypersensitivity reactions (immediate-type allergies) and, in some cases, to facilitate allergen immunotherapy (desensitization). The FDA has a long history of regulating these extracts, although many remain 'non-standardized,' meaning their potency is not measured by a federally established reference standard, but rather by the weight-to-volume (w/v) ratio or protein nitrogen unit (PNU) content.
The primary clinical mechanism of Astacus Astacus revolves around its allergenic properties, specifically targeting the human immune system's IgE-mediated pathways. At the molecular level, the extract contains highly conserved proteins, most notably tropomyosin (the primary allergen in crustaceans), arginine kinase, and myosin light chain. When these proteins are introduced to a sensitized individual—typically through skin prick testing or intradermal injection—they bind to specific Immunoglobulin E (IgE) antibodies that are already attached to the surface of mast cells and basophils.
This binding event triggers 'cross-linking' of the IgE receptors, leading to immediate degranulation of the mast cells. This process releases a cascade of inflammatory mediators, including histamine, leukotrienes, and prostaglandins. In a controlled diagnostic setting, this results in a localized 'wheal and flare' reaction (a raised bump surrounded by redness), which allows the healthcare provider to confirm a crustacean allergy. When used in immunotherapy, the mechanism shifts toward inducing immunological tolerance by modulating T-cell responses and increasing the production of IgG4 'blocking' antibodies.
The pharmacokinetics of Astacus Astacus extracts differ significantly from traditional oral or intravenous medications because the extract is typically administered via the epicutaneous (skin surface) or subcutaneous (under the skin) routes.
Astacus Astacus is primarily indicated for:
Astacus Astacus is available in the following dosage forms:
> Important: Only your healthcare provider can determine if Astacus Astacus is right for your specific condition.
Dosage for Astacus Astacus is highly individualized and must be performed by a trained specialist in a clinical setting equipped to handle anaphylaxis.
Astacus Astacus extracts are used in children for allergy diagnosis. However, the procedure must be modified based on the child's age and skin sensitivity.
No specific dosage adjustments are required for renal impairment, as the systemic load of the extract during diagnostic testing is minimal. However, patients with end-stage renal disease may have altered skin reactivity (uremic pruritus), which can interfere with the interpretation of skin tests.
No dosage adjustments are necessary for patients with liver disease. The metabolism of these protein-based extracts does not rely on hepatic pathways.
Elderly patients may have reduced skin reactivity (decreased mast cell density or responsiveness). Healthcare providers may need to use positive controls (histamine) more carefully to ensure the validity of the test results.
Astacus Astacus extracts are NOT for self-administration. They must be administered by a healthcare professional.
In the context of diagnostic testing, a missed appointment simply requires rescheduling. For immunotherapy, a missed dose may require a 'step-back' in dosage. If more than 2-4 weeks have passed since the last injection, the doctor may need to reduce the dose to prevent an allergic reaction upon resumption.
An 'overdose' in the context of Astacus Astacus refers to the administration of too much allergen to a highly sensitive patient, leading to a systemic allergic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing testing or treatment with Astacus Astacus will experience localized reactions at the site of administration. These are generally expected and indicate the body's immunological recognition of the substance.
These reactions are more significant and may require monitoring or minor medical intervention.
> Warning: Stop taking Astacus Astacus and call your doctor immediately if you experience any of these.
In the context of long-term immunotherapy, patients may develop a persistent sensitivity to the extract. There is also a theoretical risk of developing 'serum sickness,' a Type III hypersensitivity reaction characterized by joint pain, fever, and rash, though this is exceedingly rare with modern purified extracts.
No FDA black box warnings for Astacus Astacus. However, all allergenic extracts carry a general class warning regarding the risk of severe non-fatal and fatal systemic allergic reactions. These extracts must only be administered by physicians who are exceptionally experienced in the treatment of anaphylaxis and the management of respiratory emergencies.
Report any unusual symptoms to your healthcare provider.
Astacus Astacus extract is a potent biological agent that must be handled with extreme caution. It is intended only for diagnostic or therapeutic use by qualified medical professionals. Patients must be observed for at least 30 minutes following any administration of the extract, as most life-threatening systemic reactions occur within this window.
While Astacus Astacus does not have a specific individual black box warning, the FDA requires a general warning for the class of Allergenic Extracts. This warning states that these products can cause severe, life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma or those taking beta-blockers are at a significantly higher risk of complications if a reaction occurs.
Astacus Astacus generally does not affect the ability to drive. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until they are fully cleared by a medical professional. Vasovagal reactions (fainting) can also occur, so patients should ensure they feel stable before leaving the clinic.
Alcohol consumption should be avoided for 24 hours before and after testing. Alcohol can increase blood flow to the skin (vasodilation), which may exacerbate local reactions or potentially accelerate the systemic absorption of the allergen.
Discontinuing Astacus Astacus testing has no withdrawal effects. In immunotherapy, stopping the injections will result in a gradual loss of the immunological tolerance that was being built, eventually returning the patient to their baseline level of allergy sensitivity.
> Important: Discuss all your medical conditions with your healthcare provider before starting Astacus Astacus.
Astacus Astacus administration will not interfere with standard blood chemistries or hematology. However, it is designed specifically to affect Skin Prick Tests and Serum IgE (RAST/ImmunoCAP) tests. The presence of the extract in the skin will intentionally alter the local dermatological profile for diagnostic purposes.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Astacus Astacus must NEVER be used in the following circumstances:
Patients who are allergic to Astacus Astacus (Noble Crayfish) are highly likely to show cross-reactivity with other crustaceans, including:
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Astacus Astacus.
Astacus Astacus is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not the direct effect of the extract on the fetus, but the risk of systemic anaphylaxis in the mother. Anaphylaxis can lead to maternal hypotension, which causes uterine hypoperfusion and fetal hypoxia (lack of oxygen). Therefore, skin testing and the initiation of immunotherapy are generally avoided during pregnancy. If a patient is already on a maintenance dose of immunotherapy and becomes pregnant, the physician may choose to continue the treatment at a constant or reduced dose.
It is not known whether the allergenic proteins in Astacus Astacus are excreted in human milk. However, because these are large proteins that are typically broken down in the maternal digestive tract if absorbed systemically, the risk to a nursing infant is considered extremely low. The primary consideration remains the mother's safety during the administration procedure.
Astacus Astacus extracts are frequently used in pediatric allergy clinics. Children as young as infants can be tested, though skin reactivity may be lower in those under 2 years of age. The psychological impact of needle-based testing must be considered, and 'multi-test' devices that apply several allergens at once with minimal discomfort are often used. Immunotherapy for food allergies in children remains largely investigational and should only be conducted in specialized centers.
Clinical studies of Astacus Astacus did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, elderly patients have thinner skin and potentially reduced mast cell responses, which may lead to smaller wheal sizes. Furthermore, the higher prevalence of cardiovascular disease and the use of medications like beta-blockers or ACE inhibitors in this population require extra caution.
No dosage adjustment is required for patients with renal impairment. However, clinicians should be aware that uremia (high levels of urea in the blood) can suppress skin test reactivity, potentially leading to false-negative results in patients with advanced kidney disease.
There are no specific precautions or dosage adjustments for patients with hepatic impairment, as the clearance of the extract's protein components does not involve the liver's metabolic pathways.
> Important: Special populations require individualized medical assessment.
Astacus Astacus works through the induction of a Type I hypersensitivity cascade. The extract contains specific pathogen-related proteins (PRPs), primarily tropomyosin (Ast a 1). Upon contact with the interstitial fluid of the dermis, these proteins are recognized by IgE antibodies bound to the high-affinity receptor FcεRI on the surface of mast cells. This recognition triggers a signal transduction pathway involving tyrosine kinases (such as Lyn and Syk), leading to an influx of calcium ions and the subsequent exocytosis (release) of pre-formed inflammatory mediators like histamine. This localized reaction is the 'gold standard' for identifying clinical sensitivity.
| Parameter | Value |
|---|---|
| Bioavailability | Negligible (Epicutaneous); Variable (Subcutaneous) |
| Protein Binding | Primarily binds to IgE and IgG antibodies |
| Half-life | 1-4 hours (local tissue clearance) |
| Tmax | 15-20 minutes (for local reaction) |
| Metabolism | Proteolytic degradation by local and systemic proteases |
| Excretion | Renal (as small peptide fragments) |
Astacus Astacus is classified as an Allergenic Extract. Within the Electronic Product Code (EPC) system, it is uniquely associated with Vitamin C [EPC] (due to its raw biological composition) and Methylxanthine [EPC] (likely due to trace constituents or specific manufacturing processes).
Common questions about Astacus Astacus
Astacus Astacus, derived from the Noble Crayfish, is primarily used as a diagnostic tool to identify individuals with crustacean or shellfish allergies. In a clinical setting, an allergist applies a small amount of the extract to the skin via a prick or scratch to see if an allergic reaction occurs. This 'skin prick test' helps confirm whether a patient's symptoms, such as hives or swelling after eating seafood, are caused by a true IgE-mediated allergy. Occasionally, it may be used in specialized research for allergen immunotherapy to help desensitize severely allergic patients. It is also classified in some contexts as a source of Vitamin C and other bioactive compounds.
The most common side effects are localized to the area where the extract was applied or injected. Patients typically experience a 'wheal and flare' reaction, which consists of a raised, itchy bump similar to a mosquito bite, surrounded by a patch of red, warm skin. This reaction is actually the intended result of a diagnostic test and usually appears within 15 minutes. Other common effects include localized itching, mild swelling, and tenderness at the site. These symptoms generally resolve on their own within a few hours without the need for intensive treatment.
It is strongly recommended to avoid alcohol for at least 24 hours before and after being tested with Astacus Astacus extract. Alcohol acts as a vasodilator, meaning it widens the blood vessels and increases blood flow to the skin. This can lead to exaggerated skin reactions, potentially causing a false-positive result or making a local reaction much more uncomfortable. Furthermore, alcohol can increase the speed at which an allergen is absorbed into the bloodstream, which may theoretically increase the risk of a systemic or 'whole-body' allergic reaction. Always follow your doctor's specific pre-test instructions regarding diet and alcohol.
Astacus Astacus is generally deferred during pregnancy unless the diagnostic information is absolutely essential for the mother's immediate health. While the extract itself does not directly harm the fetus, the risk of a systemic allergic reaction (anaphylaxis) poses a significant danger. Anaphylaxis can cause a sharp drop in the mother's blood pressure, which reduces the flow of oxygen and nutrients to the placenta and the developing baby. For this reason, most allergists recommend waiting until after delivery to perform skin testing or to start new immunotherapy treatments. If you are already on a stable maintenance dose of immunotherapy, your doctor will decide if it is safer to continue or pause the treatment.
When used for diagnostic skin testing, Astacus Astacus works very rapidly. A visible reaction, if the patient is allergic, typically begins to appear within 5 to 10 minutes of the skin prick. The reaction usually reaches its maximum size and intensity between 15 and 20 minutes, which is when the healthcare provider will measure the results. If the extract is being used for immunotherapy (desensitization), the 'work' happens over a much longer period, often taking 6 months to a year of regular injections to see a significant reduction in allergy symptoms. The diagnostic onset is immediate, but the therapeutic benefit is a long-term process.
Since Astacus Astacus is usually administered as a one-time diagnostic test, 'stopping' it is not typically an issue. However, if you are receiving it as part of a long-term immunotherapy program, you can stop the injections at any time without experiencing physical withdrawal symptoms. It is important to note that stopping immunotherapy prematurely will likely result in the return of your original seafood allergy symptoms, as your immune system will lose the tolerance it was gradually building. You should always discuss the discontinuation of any long-term treatment plan with your allergist to understand the implications for your allergy management.
If you miss an appointment for a diagnostic skin test, you simply need to reschedule with your healthcare provider. If you are undergoing immunotherapy and miss a scheduled injection, you should contact your allergist as soon as possible. Missing a dose during the 'build-up' phase of immunotherapy may require your doctor to repeat the previous dose or even reduce the dose for your next visit to ensure safety. Missing a dose during the 'maintenance' phase is less critical but still requires a specific protocol to get back on track. Never attempt to 'double up' on doses to make up for a missed one.
There is no clinical evidence to suggest that Astacus Astacus extract causes weight gain. The amount of the substance used in diagnostic testing is microscopic, and even in long-term immunotherapy, the protein load is far too low to affect metabolic rate or fat storage. Unlike some other medications, such as certain steroids or antidepressants, allergenic extracts do not interact with the hormones or brain centers that regulate appetite and weight. If you notice weight changes while undergoing allergy treatment, it is likely due to other factors, such as lifestyle changes or other medications, and should be discussed with your doctor.
Astacus Astacus can interact with several types of medications, particularly those that affect the immune system or the body's response to adrenaline. Antihistamines, for example, will block the skin reaction and must be stopped several days before testing. More seriously, beta-blockers used for heart conditions can make an allergic reaction much more dangerous and harder to treat. You must provide your healthcare provider with a complete list of all medications, including over-the-counter drugs and herbal supplements, before any procedure involving Astacus Astacus. This ensures that the test results are accurate and that the procedure is as safe as possible.
The concept of 'generic' vs. 'brand name' is slightly different for allergenic extracts like Astacus Astacus. Because these are biological products derived from natural sources, they are often produced by specialized laboratories (such as Greer Laboratories or HollisterStier) and labeled by their source name. Most Astacus Astacus extracts are 'non-standardized,' meaning there is no single 'brand' that serves as the reference for others. Different manufacturers may produce extracts that vary slightly in their protein concentration. Your allergist will typically use a trusted supplier, and while the source may vary, the clinical application remains the same across the industry.